<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03809637</url>
  </required_header>
  <id_info>
    <org_study_id>4-2016-0389</org_study_id>
    <nct_id>NCT03809637</nct_id>
  </id_info>
  <brief_title>A Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma</brief_title>
  <official_title>Phase II Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The yearly incidence of soft-tissue sarcomas(STS) in the USA is roughly 11,280 cases, and&#xD;
      metastatic STS have a median overall survival of about 12 months. After the standard 1st line&#xD;
      chemotherapy with doxorubicin, the only a few treatment option is available. Recently,&#xD;
      pemetrexed, a novel multitargeted antifolate, has shown modest activity as a single agent&#xD;
      lung cancer and mesothelioma. In patients with refractory STS, pemetrexed is well tolerated&#xD;
      and moderately effective. Based on the background, investigators planned to conduct the phase&#xD;
      II trial of pemetrexed in combination with cisplatin for metastatic/recurred soft-tissue&#xD;
      sarcomas.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 10, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free rate</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>every 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>pemetrexed+cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with metastatic sarcoma who underwent one chemotherapy regimens are treated with the combination of pemetrexed and cisplatin, and the treatment is repeated until the disease progression. pemetrexed 500 mg / m2 (day 1) and cisplatin 75 mg / m2 (day 1) are intravenously injected. 21 days is one cycle, and it is carried out by co-administration up to 6 cycles. After 7 cycles, intravenous injection of pemetrexed alone at intervals of 3 weeks until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed, cisplatin</intervention_name>
    <description>Pemetrexed 500mg/m2, Intravenous, Q 3weeks. Cisplatin 75mg/m2, Intravenous, Q 3weeks. Combination administration : up to 6cycles After 6 cycle, pemetrexed alone is administered.</description>
    <arm_group_label>pemetrexed+cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed advanced bone and soft tissue sarcoma with prior chemotherapy&#xD;
             including anthracycline or ifosfamide&#xD;
&#xD;
          2. Measurable or evaluable disease (RECIST 1.1.)&#xD;
&#xD;
          3. Age ≥19 years&#xD;
&#xD;
          4. ECOG performance status of 0-2&#xD;
&#xD;
          5. Adequate laboratory findings&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1500 /µL&#xD;
&#xD;
               -  Platelet count ≥ 75,000/ µL&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) &lt; 3 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Total bilirubin &lt;1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          6. more than 3 months of expected survival&#xD;
&#xD;
          7. Provision of written informed consent prior to any study procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who has had chemotherapy, radiotherapy, or biological therapy within 2 weeks&#xD;
             prior to entering the study'&#xD;
&#xD;
          2. Patient is pregnant or breastfeeding, or expecting to conceive or father children&#xD;
             within the projected duration of the study.&#xD;
&#xD;
          3. Resectable lung metastases&#xD;
&#xD;
          4. Uncontrolled or active CNS metastasis and/or carcinomatous meningitis&#xD;
&#xD;
          5. Other co-existing malignancies or malignancies diagnosed within the last 3 years with&#xD;
             the exception of basal cell carcinoma, thyroid cancer or cervical cancer in situ.&#xD;
&#xD;
          6. Uncontrolled medical conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 15, 2019</study_first_submitted>
  <study_first_submitted_qc>January 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Hyo Song Kim</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

